{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:23:40Z","timestamp":1791822220720,"version":"4.3.4"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ajem.2024.12.006","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:05:21Z","timestamp":1733616321000},"page":"273.e5-273.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Acute hyperglycemic hyperosmolar syndrome associated with capivasertib, a new, oral targeted therapy for advanced breast cancer"],"prefix":"10.1016","volume":"88","author":[{"given":"Aileen","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niv","family":"Hakami-Majd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Ozaki","family":"Whall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2024.12.006_bb0005","series-title":"Truqap (capivasertib) [package insert]","year":"2024"},{"issue":"16","key":"10.1016\/j.ajem.2024.12.006_bb0010","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.3390\/cancers13163949","article-title":"The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review","volume":"13","author":"Rascio","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajem.2024.12.006_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.822333","article-title":"Akt: a potential drug target for metabolic syndrome","volume":"13","author":"Miao","year":"2022","journal-title":"Front Physiol"},{"issue":"22","key":"10.1016\/j.ajem.2024.12.006_bb0020","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ajem.2024.12.006_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103697","article-title":"Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study","volume":"9","author":"Rugo","year":"2024","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.ajem.2024.12.006_bb0030","first-page":"e204","article-title":"Alpelisib-induced diabetic ketoacidosis: a pharmacovigilance analysis of the FDA adverse event reporting system and review of the literature","volume":"24","author":"Ziegengeist","year":"2024","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"10.1016\/j.ajem.2024.12.006_bb0035","article-title":"Capivasertib-induced diabetic ketoacidosis in a patient with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative (ER+\/HER2-) metastatic breast cancer and no prior history of diabetes mellitus: a case report","volume":"16","author":"Rodriguez","year":"2024","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.ajem.2024.12.006_bb0040","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ajem.2018.09.053","article-title":"Comparison of two glycemic discharge goals in ED patients with hyperglycemia, a randomized trial","volume":"37","author":"Driver","year":"2019","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ajem.2024.12.006_bb0045","series-title":"Referenced with permission from the NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) for breast cancer V.5.2024","year":"2024"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675724006892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675724006892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:58:24Z","timestamp":1738929504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675724006892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":9,"alternative-id":["S0735675724006892"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2024.12.006","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute hyperglycemic hyperosmolar syndrome associated with capivasertib, a new, oral targeted therapy for advanced breast cancer","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}